Ribavirin 200 mg Tablets Under Fasting Conditions

ClinicalTrials.gov ID: NCT00835146

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00835146. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Relative Bioavailability Study of Ribavirin 200 mg Tablets Under Fasting Conditions

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of this study is to compare the relative bioavailability of ribavirin 200 mg tablets (manufactured by TEVA Pharmaceutical Industries, Ltd. and distributed by TEVA Pharmaceuticals USA) with that of COPEGUS™ 200 mg tablets (Roche) in healthy, adult, non-smoking, females (who are unable to become pregnant) under fasting conditions.

Study identification

NCT ID: NCT00835146
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Teva Pharmaceuticals USA; Industry
Enrollment: 28 participants

Conditions and interventions

Conditions

Healthy

Interventions

Ribavirin 200 mg tablets Drug
COPEGUS™ Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 2003 (Type not available)
Primary completion: Oct 2003 (Actual)
Completion: Oct 2003 (Actual)
Last update posted: Aug 20, 2024

2003

United States locations

U.S. sites: 2
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Novum Pharmaceutical Research Services	Houston	Texas	77042	—
Bioassay Laboratory, Inc.	Houston	Texas	77099	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00835146, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 20, 2024 · Synced Nov 12, 2026